Skip to main content
. Author manuscript; available in PMC: 2016 Jun 8.
Published in final edited form as: Cancer Cell. 2015 Jun 8;27(6):864–876. doi: 10.1016/j.ccell.2015.05.004

Figure 6. ClpP expression correlates with sensitivity to A2-32-01 in primary AML cells.

Figure 6

(A) Expression of ClpP and Actin in primary normal hematopoietic cells, primary AML patient samples, and OCI-AML2 cells was determined by immunoblotting.

(B, C) Effect of A2-32-01 on the viability of primary normal hematopoietic cells (B) and primary AML cells (C) assessed after a 48 hour period of exposure. Mean ± SD percent of viable cells was measured by Annexin V/PI staining and flow cytometry.

(D) Correlation analysis of ClpP expression and cell viability of primary AML cells. Cell viability was measured by Annexin-V/PI staining 48 hours after treatment with 80 µM of A2-32-01.